PL2670751T3 - Metoda wytwarzania związku proleku inhibitora wiązania HIV i produktów pośrednich - Google Patents

Metoda wytwarzania związku proleku inhibitora wiązania HIV i produktów pośrednich

Info

Publication number
PL2670751T3
PL2670751T3 PL12704960T PL12704960T PL2670751T3 PL 2670751 T3 PL2670751 T3 PL 2670751T3 PL 12704960 T PL12704960 T PL 12704960T PL 12704960 T PL12704960 T PL 12704960T PL 2670751 T3 PL2670751 T3 PL 2670751T3
Authority
PL
Poland
Prior art keywords
intermediates
methods
prodrug compound
inhibitor prodrug
hiv attachment
Prior art date
Application number
PL12704960T
Other languages
English (en)
Inventor
Jonathan Clive Tripp
Dayne Dustan Fanfair
Mitchell J Schultz
Saravanababu Murugesan
Richard J Fox
Chung-Pin H Chen
Sabrina E Ivy
Joseph Francis Payack
Wendel W Doubleday
Original Assignee
Viiv Healthcare Uk No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 4 Ltd filed Critical Viiv Healthcare Uk No 4 Ltd
Publication of PL2670751T3 publication Critical patent/PL2670751T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL12704960T 2011-01-31 2012-01-27 Metoda wytwarzania związku proleku inhibitora wiązania HIV i produktów pośrednich PL2670751T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437821P 2011-01-31 2011-01-31
PCT/US2012/022851 WO2012106189A1 (en) 2011-01-31 2012-01-27 Methods of making hiv attachment inhibitor prodrug compound and intermediates
EP20120704960 EP2670751B1 (en) 2011-01-31 2012-01-27 Methods of making hiv attachment inhibitor prodrug compound and intermediates

Publications (1)

Publication Number Publication Date
PL2670751T3 true PL2670751T3 (pl) 2015-09-30

Family

ID=45688987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12704960T PL2670751T3 (pl) 2011-01-31 2012-01-27 Metoda wytwarzania związku proleku inhibitora wiązania HIV i produktów pośrednich

Country Status (25)

Country Link
US (1) US8436168B2 (pl)
EP (1) EP2670751B1 (pl)
JP (1) JP6006236B2 (pl)
KR (1) KR101848533B1 (pl)
CN (1) CN103339130B (pl)
AR (1) AR085052A1 (pl)
AU (1) AU2012212508B2 (pl)
BR (1) BR112013018159A2 (pl)
CA (1) CA2826260C (pl)
CY (1) CY1116505T1 (pl)
DK (1) DK2670751T3 (pl)
EA (1) EA021726B1 (pl)
ES (1) ES2539908T3 (pl)
HR (1) HRP20150616T1 (pl)
HU (1) HUE026880T2 (pl)
IL (1) IL227302A (pl)
MX (1) MX2013008371A (pl)
PL (1) PL2670751T3 (pl)
PT (1) PT2670751E (pl)
RS (1) RS54055B1 (pl)
SG (1) SG191841A1 (pl)
SI (1) SI2670751T1 (pl)
SM (1) SMT201500169B (pl)
TW (1) TW201309692A (pl)
WO (1) WO2012106189A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20100198192A1 (en) 2009-01-20 2010-08-05 Eugene Serina Anchor deployment devices and related methods
PT2812332T (pt) 2012-02-08 2017-11-15 Viiv Healthcare Uk (No 4) Ltd Métodos para a preparação do composto profármaco piperazina inibidor da conjugação ao vih
JP6693891B2 (ja) * 2014-06-23 2020-05-13 フリー フォーム ファイバーズ リミテッド ライアビリティ カンパニー 核燃料構造体及び核燃料構造体を作製する方法
RU2017122191A (ru) 2014-12-18 2019-01-18 ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД Способ получения галоидированных азаиндольных соединений с использованием PуBroP
KR20170096021A (ko) 2014-12-18 2017-08-23 비브 헬스케어 유케이 (넘버4) 리미티드 보록신을 사용하여 할로겐화된 아자인돌 화합물을 제조하는 방법
CA2978599C (en) * 2015-03-05 2022-09-06 Ancora Heart, Inc. Devices and methods of visualizing and determining depth of penetration in cardiac tissue
JP6692542B2 (ja) * 2016-05-13 2020-05-13 学校法人早稲田大学 簡便、迅速、高精度な皮膚pHの測定法
US12157753B2 (en) 2019-01-17 2024-12-03 ViiV Healthcare UK (No.4) Limited Process for preparing Fostemsavir

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine

Also Published As

Publication number Publication date
MX2013008371A (es) 2013-08-12
EP2670751A1 (en) 2013-12-11
CY1116505T1 (el) 2017-03-15
AR085052A1 (es) 2013-08-07
SI2670751T1 (sl) 2015-07-31
DK2670751T3 (en) 2015-07-20
RS54055B1 (sr) 2015-10-30
CA2826260C (en) 2018-09-04
US8436168B2 (en) 2013-05-07
HUE026880T2 (en) 2016-08-29
US20130030178A1 (en) 2013-01-31
CN103339130A (zh) 2013-10-02
CN103339130B (zh) 2015-05-06
JP2014503594A (ja) 2014-02-13
EA021726B1 (ru) 2015-08-31
EA201391123A1 (ru) 2013-12-30
SG191841A1 (en) 2013-08-30
EP2670751B1 (en) 2015-04-22
BR112013018159A2 (pt) 2018-09-11
PT2670751E (pt) 2015-07-29
JP6006236B2 (ja) 2016-10-12
AU2012212508B2 (en) 2016-01-14
IL227302A0 (en) 2013-09-30
TW201309692A (zh) 2013-03-01
SMT201500169B (it) 2015-09-07
ES2539908T3 (es) 2015-07-07
AU2012212508A1 (en) 2013-09-19
WO2012106189A1 (en) 2012-08-09
KR20140014154A (ko) 2014-02-05
HRP20150616T1 (hr) 2015-07-03
KR101848533B1 (ko) 2018-04-12
IL227302A (en) 2016-10-31
CA2826260A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
IL227302A0 (en) Methods for preparing a pro-drug compound that inhibits HIV conjugation and intermediates
SMT201600060B (it) Procedimenti e intermedi per la produzione di un inibitore di jak
GB2554620B (en) Method of acoustic surveying
SG10201605196PA (en) Novel Inhibitor Compounds Of Phosphodiesterase Type 10A
ZA201303433B (en) Inhibitors of hiv replication
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
IL229459B (en) Use of thiazolide compounds against hiv
IL231269A0 (en) Preparations for the treatment of HIV
PL3287131T3 (pl) Terapeutyczne zastosowania ektoiny
IL232623A0 (en) Sublingual administration of statins
GB201120644D0 (en) Herbicidal uses of compounds
PT2812332T (pt) Métodos para a preparação do composto profármaco piperazina inibidor da conjugação ao vih
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
ZA201308185B (en) Novel precursors of glutamate derivatives
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
IL227490A0 (en) quinazolinone inhibitors of dynein
IL230977A (en) A crystalline form of relapaldib
PL2793862T3 (pl) Sposób współprzetwarzania i preparat związku będącego prolekiem inhibitora przyłączania HIV i zaróbek
GB201108347D0 (en) Polymprphic form of compound
HK1194020A (en) Solid state forms of hiv inhibitor
IL243319A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
GB201108346D0 (en) Polymorphic form of compound
GB201111385D0 (en) Prodrugs of fluvoxamine and uses thereof
GB201111380D0 (en) Prodrugs of fluvoxamine and uses thereof
PH32011000651S1 (en) Piece of jewellery